Modulation of POPDC1 Expression by Phenothiazine and Trifluoperazine Suppress Colon Cancer Growth and Migration.

Cell Movement Cell Proliferation Colonic Neoplasms / drug therapy Humans Proliferating Cell Nuclear Antigen / genetics Trifluoperazine / pharmacology
Colon cancer POPDC calmodulin antagonist

Journal

Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625

Informations de publication

Date de publication:
01 Aug 2022
Historique:
received: 12 05 2022
entrez: 29 8 2022
pubmed: 30 8 2022
medline: 1 9 2022
Statut: epublish

Résumé

The aim of this study was to investigate the effects of CaM antagonist, PTZ, and TFP on cell proliferation and migration of colon cancer cells and its impact on POPDC protein expression. The 50% inhibitory concentration (IC50) of PTZ and TFP in SW1116, SW480, HCT-15, and COLO205 colon cancer cell lines are measured using MTT. Western blot and immunocytochemistry were used to determine the expression of PCNA, cyclin D1 (CD1), and POPDC proteins. Cell migration was observed using a scratch wound-healing assay. Treatment with PTZ and TFP inhibited colon cancer cells growth in a dose-dependent manner. PTZ and TFP significantly inhibited the activation of proliferation markers, PCNA and CD1, and the migration of colon cancer cells. Furthermore, POPDC protein was significantly suppressed in all cell types of colon cancer, particularly in SW480. Finally, the CaM antagonist upregulates the POPDC1 expression in colon cancer cells. These findings suggest that CaM antagonists suppress colon cancer cells proliferation via downregulation of CD1 and PCNA. In addition, POPDC protein could be used as a biomarker in colon cancer, and CaM antagonist could be used to regulate POPDC1 expression. This study suggests that targeting POPDC1 with CaM inhibition could be a potential therapeutic strategy for colon cancer treatment. <br />.

Identifiants

DOI: 10.31557/APJCP.2022.23.8.2863 PMID: 36037145 PMC: PMC9741886
pubmed: 36037145
doi: 10.31557/APJCP.2022.23.8.2863
pmc: PMC9741886
pii:
doi:

Substances chimiques

Proliferating Cell Nuclear Antigen 0
Trifluoperazine 214IZI85K3

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2863-2871

Références

Int J Mol Sci. 2020 Jan 24;21(3):
pubmed: 31991573
Cell. 2017 Feb 9;168(4):670-691
pubmed: 28187288
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Onco Targets Ther. 2019 Feb 18;12:1279-1291
pubmed: 30863095
Development. 2001 Jun;128(11):2085-93
pubmed: 11493530
Tissue Barriers. 2018;6(4):1-12
pubmed: 30307367
Tumour Biol. 2014 Jan;35(1):257-64
pubmed: 24222327
Sci Rep. 2018 Oct 25;8(1):15753
pubmed: 30361678
Prog Biophys Mol Biol. 2016 Jan;120(1-3):28-36
pubmed: 26772438
Asian Pac J Cancer Prev. 2009;10(6):1163-6
pubmed: 20192604
Biosci Rep. 2017 Nov 21;37(6):
pubmed: 28954821
J Cell Biochem. 2019 Sep;120(9):15756-15765
pubmed: 31081173
Mol Cancer Ther. 2017 Jan;16(1):217-227
pubmed: 28062709
Br J Pharmacol. 2022 Jun;179(12):2829-2843
pubmed: 33533478
Medicine (Baltimore). 2018 Dec;97(50):e13752
pubmed: 30558098
Toxicology. 2015 Apr 1;330:44-54
pubmed: 25686698
Medicine (Baltimore). 2020 Apr;99(16):e19755
pubmed: 32311975
Med Oral Patol Oral Cir Bucal. 2013 Mar 01;18(2):e174-9
pubmed: 23229269
Drug Discov Today. 2016 Dec;21(12):1920-1927
pubmed: 27458118
Int J Mol Sci. 2020 Mar 13;21(6):
pubmed: 32183020
Sci Rep. 2016 Jun 09;6:27540
pubmed: 27277973
Biochim Biophys Acta. 2014 Feb;1843(2):398-435
pubmed: 24188867
PLoS One. 2013 Apr 08;8(4):e61362
pubmed: 23593472
Front Pharmacol. 2019 Sep 13;10:1029
pubmed: 31572198
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
JAMA Oncol. 2022 Mar 01;8(3):420-444
pubmed: 34967848
Mol Med Rep. 2016 May;13(5):3715-23
pubmed: 27035868
Cell Death Dis. 2018 Sep 26;9(10):1006
pubmed: 30258182
Cancer Chemother Pharmacol. 2004 Mar;53(3):267-75
pubmed: 14663628
PLoS One. 2013;8(1):e55719
pubmed: 23383271
Dig Dis Sci. 2014 May;59(5):992-1000
pubmed: 24442236
Anticancer Res. 2009 Aug;29(8):3049-52
pubmed: 19661314
Br J Cancer. 2005 Aug 8;93(3):338-45
pubmed: 16012517
J Cell Sci. 2005 Oct 15;118(Pt 20):4667-78
pubmed: 16188940
J Mol Med (Berl). 2016 Dec;94(12):1313-1326
pubmed: 27695879
Cell Signal. 2017 Dec;40:156-165
pubmed: 28939104
Mucosal Immunol. 2018 Sep;11(5):1363-1374
pubmed: 29907869

Auteurs

Fiona Macniesia Thomas (FM)

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Kota Kinabalu 88400, Sabah, Malaysia.

Suhaini Sudi (S)

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Kota Kinabalu 88400, Sabah, Malaysia.

Falah Abas Muhamad Salih (FA)

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Kota Kinabalu 88400, Sabah, Malaysia.
Department of Medical Laboratory Science, Cihan University, Erbil, Iraq.

Praneetha Palasuberniam (P)

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Kota Kinabalu 88400, Sabah, Malaysia.

Latifah Suali (L)

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Kota Kinabalu 88400, Sabah, Malaysia.

Mohd Hijaz Mohd Sani (MH)

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Kota Kinabalu 88400, Sabah, Malaysia.

Caroline Sunggip (C)

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Kota Kinabalu 88400, Sabah, Malaysia.
Borneo Medical and Health Research Centre, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Kota Kinabalu 88400, Sabah, Malaysia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes physiologiques › Mouvement cellulaire › Modulation of POPDC1 Expression by...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › Modulation of POPDC1 Expression by...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Tumeurs de l'intestin › Tumeurs du côlon › Modulation of POPDC1 Expression by...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Modulation of POPDC1 Expression by...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Antigène nucléaire de prolifération cellulaire › Modulation of POPDC1 Expression by...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérocycliques 3 noyaux › Phénothiazines › Trifluopérazine › Modulation of POPDC1 Expression by...